Session » RA – Treatment Poster II

Date: Sunday, November 13, 2022

Time: 9:00AM-10:30AM

Meeting: ACR Convergence 2022

9:00AM-10:30AM: Abstract Number: 0932

Accelerated Waning of Protective Immunity After SARS-CoV-2 mRNA Vaccination in Patients Treated with Biological and Targeted Synthetic Disease Modifying Antirheumatic Drugs

9:00AM-10:30AM: Abstract Number: 0922

Alteration of the Cardiometabolic and Cardiovascular Proteome in Rheumatoid Arthritis. Modulation by Methotrexate and Tofacitinib

9:00AM-10:30AM: Abstract Number: 0938

Baseline Predictors of Disease Flare upon csDMARD Withdrawal in Patients with Rheumatoid Arthritis in Sustained Remission After DAS-driven Therapy: Role of the Systemic Autoimmune Status and Peripheral Joint Ultrasound Across a 5-year Follow-up

9:00AM-10:30AM: Abstract Number: 0937

Conventional Synthetic DMARDs Re-treatment for Rheumatoid Arthritis Flare During Drug-free Follow-up: Rate, Dynamics and Quality of Clinical Response

9:00AM-10:30AM: Abstract Number: 0930

Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Receiving Folic Acid Supplementation

9:00AM-10:30AM: Abstract Number: 0921

Effects of Methotrexate on the Liver Function and Disease Activity of Newly Diagnosed RA Patients Depending on the Cardiometabolic Profile

9:00AM-10:30AM: Abstract Number: 0918

Efficacy and Safety of Filgotinib in Patients with Inadequate Response to Methotrexate, with 4 or < 4 Poor Prognostic Factors: A Post Hoc Analysis of the FINCH 1 Study

9:00AM-10:30AM: Abstract Number: 0933

Exploratory Study of the Usefulness of TNFAIP3 Genetic Variants in Predicting Response to Methotrexate in Early Arthritis Patients

9:00AM-10:30AM: Abstract Number: 0917

Fifty-two-week Results from a Phase 3, Randomized, Double-blind, Active-controlled Clinical Trial to Compare BAT1806/BIIB800, a Proposed Tocilizumab Biosimilar, with a Tocilizumab Reference Product in Subjects with Moderate to Severe RA with an Inadequate Response to Methotrexate

9:00AM-10:30AM: Abstract Number: 0923

Identification of Cell-Specific DNA Methylation Changes Associated with MTX Treatment Response in Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0936

Immediate and Long-term Effects of the MTX Discontinuation for 1 vs. 2 Weeks on Vaccine Response to Seasonal Influenza Vaccine: A Non-inferiority Randomized Controlled Trial

9:00AM-10:30AM: Abstract Number: 0913

Impact of Disease-modifying Antirheumatic Drugs on Immunogenicity to COVID-19 Vaccine in Patients with Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0925

Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs on Pain Medication Use in Patients with Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0934

Impact of Tapering Targeted Therapy on Disease Activity Is Different Based on Concomitant Methotrexate Use in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study

9:00AM-10:30AM: Abstract Number: 0926

Methotrexate Polyglutamates Exposure – Response Modelling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate

9:00AM-10:30AM: Abstract Number: 0915

Methotrexate Therapy Results in Disparate Methotrexate Polyglutamate Profiles in Peripheral Blood Mononuclear Cells Compared with Erythrocytes

9:00AM-10:30AM: Abstract Number: 0919

Predictors of Methotrexate Monotherapy Response in Patients with Active Rheumatoid Arthritis: Results from a Multicentre, Randomized Controlled Trial

9:00AM-10:30AM: Abstract Number: 0920

Retention Rate and Safety of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients with Rheumatoid Arthritis Associated with Interstitial Lung Disease: Results from the KOBIO Registry

9:00AM-10:30AM: Abstract Number: 0927

Review of 167,990 Same Day RAPID3, CDAI Scores for 61,312 Patients Receiving DMARD Treatment for Rheumatoid Arthritis; Evaluations of Disease Assessments and Treatment Discontinuation

9:00AM-10:30AM: Abstract Number: 0931

Rituximab versus Leflunomide in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis Despite Methotrexate Treatment- an Open Label Randomized Controlled Trial

9:00AM-10:30AM: Abstract Number: 0929

Severe Low-Dose Methotrexate Toxicity in Elderly Patients with Inflammatory Rheumatic Diseases

9:00AM-10:30AM: Abstract Number: 0916

Should RA Patients with Controlled Disease Taper Methotrexate from Targeted Therapy or Continue It? Risk Differences in Sustaining Remission from a Systematic Review and Meta-analysis

9:00AM-10:30AM: Abstract Number: 0935

Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to CsDMARDs, Enriching CsDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy

9:00AM-10:30AM: Abstract Number: 0914

The Impact of Autoantibodies (RF and ACPA) on the Efficacy of Biological Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Meta-analysis of Randomized Controlled Trials

9:00AM-10:30AM: Abstract Number: 0928

Use of Disease Modifying Anti-rheumatic Drugs and Risk of Multiple Myeloma in US Veterans with Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0924

Vitamin B12 Status and Hyperhomocysteinemia in Patients with Rheumatoid Arthritis Treated with Methotrexate and Folic Acid

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].